Photocure is a commercial-stage Norwegian specialty pharmaceutical company that currently markets Hexvix/Cysview for diagnosing and managing bladder cancer. Recently, the company announced that the US Centers for Medicare & Medicaid Services (CMS) issued a final rule that would improve reimbursement for a large number of procedures. Also, following positive Phase III results in the surveillance setting, the company filed a supplemental New Drug Application (sNDA) which, if approved, would dramatically increase the addressable market for Hexvix/Cysview.
Major reimbursement change in the US
The CMS has issued a final rule, which is set to take effect at the beginning of 2018. The rule significantly improves the reimbursement (by ~$1,000) for certain blue light cystoscopy (BLC) with Hexvix/Cysview procedures in Medicare patients. As 73.4% of bladder cancer patients are over 65, according to the National Cancer Institute, this should help accelerate penetration of the product in the US.
To read the entire report Please click on the pdf File Below: